

SUMMARY



The addition of SGLT2i to RAASi/MRA agents reduces the risk of hyperkalemia development in CKD patients



Empagliflozin use reduces the risk of hyperkalemia & does not result in hypokalemia adverse events in patients with heart failure



Evidence suggest that the addition of SGLT2i along RAASi treatment is safe and mitigates the risk of hyperkalemia that is present with RAASi treatment alone